Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
Abstract Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due to the complexity of tumor/immune/genome interactions. We implemented a multidisciplinary Molecular Tumor Board (MTB) that reviewed multi-omic cancer characte...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-09-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-022-00309-0 |